NASDAQ:ERYP ERYTECH Pharma (ERYP) Stock Forecast, Price & News $0.94 0.00 (0.00%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$0.86▼$0.9450-Day Range$0.70▼$1.2252-Week Range$0.30▼$1.47Volume3,985 shsAverage Volume107,945 shsMarket Capitalization$32.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About ERYTECH Pharma (NASDAQ:ERYP) StockERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.Read More Receive ERYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ERYP Stock News HeadlinesMay 30, 2023 | americanbankingnews.comHead-To-Head Contrast: ERYTECH Pharma (NASDAQ:ERYP) vs. Amgen (NASDAQ:AMGN)May 26, 2023 | americanbankingnews.comERYTECH Pharma S.A. (NASDAQ:ERYP) Sees Large Increase in Short InterestJune 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 26, 2023 | americanbankingnews.comERYTECH Pharma (NASDAQ:ERYP) & Surface Oncology (NASDAQ:SURF) Head-To-Head ReviewMay 24, 2023 | finance.yahoo.comERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023May 24, 2023 | msn.comPharma Stocks Lead European Equities Sharply Lower in Wednesday TradingMay 23, 2023 | businesswire.comPHERECYDES Announces the Availability of the Exemption Document Relating to the Proposed Combination With Erytech PharmaMay 23, 2023 | finance.yahoo.comERYTECH announces the availability of the exemption document relating to the proposed combination with PherecydesJune 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 23, 2023 | msn.comPharma Stocks Lead European Equities Modestly Lower in Tuesday TradingMay 19, 2023 | msn.comEuropean Equities Rise in Friday Trading, Poised to End Week HigherMay 17, 2023 | msn.comPharma Stocks Weigh Down European Equities in Wednesday TradingMay 16, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _May 15, 2023May 16, 2023 | msn.comPharma Stocks, Vodafone Lead European Equities Lower in Tuesday TradingMay 15, 2023 | finanznachrichten.deErytech Pharma S.A.: ERYTECH Provides Update on the Announced Combination with PHERECYDESMay 15, 2023 | finance.yahoo.comERYTECH Provides Update on the Announced Combination with PHERECYDESMay 12, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _April 30, 2023May 12, 2023 | msn.comEuropean Equities Traded as American Depositary Receipts Lower Again in Wednesday US TradingMay 9, 2023 | finanznachrichten.deErytech Pharma S.A.: ERYTECH Provides Business and Financial Update for the First Quarter of 2023May 9, 2023 | theglobeandmail.comMicro Cap Bid Up Right Before Opening BellMay 9, 2023 | finance.yahoo.comERYTECH Provides Business and Financial Update for the First Quarter of 2023May 9, 2023 | finance.yahoo.comERYTECH Provides Business and Financial Update for the First Quarter of 2023April 17, 2023 | finanznachrichten.deErytech Pharma S.A.: ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital MarketApril 17, 2023 | seekingalpha.comERYTECH receives approval to transfer its listing to Nasdaq Capital MarketApril 17, 2023 | finance.yahoo.comERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital MarketApril 14, 2023 | msn.comPharma Stocks Lead European Equities Lower Friday Trading, But Index Poised to End Week HigherApril 12, 2023 | msn.comPharma Stocks Lead European Equities Higher Wednesday TradingSee More Headlines ERYP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ERYP Company Calendar Today6/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ERYP CUSIPN/A CIK1624422 Webwww.erytech.com Phone(347) 874-4438Fax33-4-78-75-56-29Employees196Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.32 Current Ratio3.65 Quick Ratio3.65 Sales & Book Value Annual Sales$32.66 million Price / Sales0.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book1.09Miscellaneous Outstanding Shares34,120,000Free Float33,458,000Market Cap$29.69 million OptionableNot Optionable Beta2.68 Key ExecutivesGil BeyenChief Executive Officer & DirectorEric SoyerChief Operating & Financial OfficerIman El-HariryChief Medical OfficerJérôme BaillyChief Quality Officer & Deputy General ManagerFrançoise Horand-PhothirathDirector-Research & Development OperationsKey CompetitorsZIVO BioscienceNASDAQ:ZIVOMiromatrix MedicalNASDAQ:MIROAxcella HealthNASDAQ:AXLAAIM ImmunoTechNYSE:AIMEntera BioNASDAQ:ENTXView All Competitors ERYP Stock - Frequently Asked Questions How have ERYP shares performed in 2023? ERYTECH Pharma's stock was trading at $0.3301 at the beginning of the year. Since then, ERYP shares have increased by 163.6% and is now trading at $0.8703. View the best growth stocks for 2023 here. Are investors shorting ERYTECH Pharma? ERYTECH Pharma saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 95,000 shares, an increase of 138.7% from the April 30th total of 39,800 shares. Based on an average trading volume of 138,400 shares, the days-to-cover ratio is presently 0.7 days. View ERYTECH Pharma's Short Interest. What other stocks do shareholders of ERYTECH Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD). When did ERYTECH Pharma IPO? (ERYP) raised $125 million in an initial public offering (IPO) on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager. What is ERYTECH Pharma's stock symbol? ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP." How do I buy shares of ERYTECH Pharma? Shares of ERYP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ERYTECH Pharma's stock price today? One share of ERYP stock can currently be purchased for approximately $0.87. How much money does ERYTECH Pharma make? ERYTECH Pharma (NASDAQ:ERYP) has a market capitalization of $29.69 million and generates $32.66 million in revenue each year. How many employees does ERYTECH Pharma have? The company employs 196 workers across the globe. How can I contact ERYTECH Pharma? ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The official website for the company is www.erytech.com. The company can be reached via phone at (347) 874-4438, via email at investors@erytech.com, or via fax at 33-4-78-75-56-29. This page (NASDAQ:ERYP) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.